RIRS with Investigational Device: Investigational endourological device used during retrograde intrarenal surgery.
Study summary
A single-arm, multicenter, international, prospective interventional study designed to evaluate the safety and performance of an investigational device during retrograde intrarenal surgery for the treatment of renal calculi.
Eligibility
Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria:
1. Diagnosis of calyceal and/or renal pelvis calculi
2. Age from 18 through 85 years
3. Maximum stone diameter between 0.5cm - 2.0cm as assessed by Non-Contrast CT scan (≤ 2 mm slice thickness) within 90 days prior to treatment
4. Willing and able to comply with all study requirements
5. Signs study-specific informed consent form
Exclusion Criteria:
1. Diagnosis of calculus of the ureter
2. BMI ≥ 42
3. Significant renal impairment: stage 3a CKD or higher (eGFR \<59mL/min)
4. Active infection, including urinary tract infection
5. Urological anatomic/congenital abnormalities
6. Previous history of struvite stone in the same renal unit
7. Taking anticoagulants that cannot be stopped before and after procedure or known coagulopathy or platelet disorder (except aspirin below 100mg/d)
8. History of gross hematuria
9. Solitary functioning kidney
10. Known allergy to device materials
11. Any severe illness that would prevent complete study participation or confound study results
12. Serious concurrent medical conditions such as heart disease (e.g., myocardial infarction within 30 days, congestive heart failure - NYHA Class IV), pulmonary disease or uncontrolled diabetes.
13. History of open-heart surgery, or cardiac arrest \< 180 days prior to the date of informed consent
14. ASA III or higher
15. Taking systemic immune suppressants
16. Dementia or psychiatric condition that prevents the participant from completing required follow up
17. Contraindication to both general and spinal anesthesia
18. Participating in another investigational study that could affect responses to the study device
19. Unwilling to accept a transfusion should one be required
20. Pregnant or considering getting pregnant within the next 3 months
21. Undergoing bilateral ureteroscopy
Primary outcome measure(s)
Procedure success — Intraoperative Successful completion of the planned procedure without device-related technical complications.
Serious Adverse Device Effects (SADEs) — 30 days post-procedure Serious adverse device effects related to the investigational device.
Stone-Free Status — 30 days post-procedure Absence of residual stone fragments on CT imaging
Trial sites (5)
Facility
City
Region
Status
Hospital Alemán
Buenos Aires
Argentina
Centre hospitalier de l'Universite de Montreal (CHUM)
Montreal
Canada
The Chinese University of Hong Kong
Hong Kong
Hong Kong
Muljibhai Patel Urological Hospital
Nadiād
India
Tauranga Urology Research Limited
Tauranga
New Zealand
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.